November 22, 2025

@michaelokun

Mucuna as a dopamine replacement in sub-Saharan Africa? Could it reshape early Parkinson care? Spoiler: We now have a positive randomized trial. A randomized trial is a study design where participants are assigned by chance to receive one treatment or another and they compare outcomes in a fair and hopefully unbiased way. Roberto Cilia and colleagues describe in a new paper in the Journal of Parkinson’s Disease how Mucuna pruriens powder performed over 12 months compared to standard levodopa (LD) plus a dopamine decarboxylase inhibitor (DDCI) in newly diagnosed folks living w/ Parkinson’s across sub-Saharan Africa. Key Points: - Mucuna pruriens delivered similar benefits on motor symptoms, non motor symptoms and quality of life compared to LD plus DDCI over 12 months. - Mucuna was generally well tolerated, however mild gastrointestinal issues were more frequent w/ Mucuna, though few discontinued therapy. - Mucuna may be a sustainable local option for regions where access to commercial levodopa is limited, however larger long term multi-center trials will be needed. My take: These trials are hard to pull off and though the sample size of 32 is small we should pay attention. Our plan www.pdplan.org calls for dopamine for all, so this article resonated w/ me. Here are 5 points to keep in mind based on the data: 1- Access matters and Mucuna pruriens could help fill treatment gaps when standard LD plus DDCI is unavailable. 2- Quality of life improved for folks taking either Mucuna or LD plus DDCI suggesting both can meaningfully reduce daily symptoms. 3- Motor symptoms responded to Mucuna in a way similar to commercial levodopa even in individuals w/ more advanced features. 4- Side effects were manageable, however some nausea or stomach issues were a bit more frequent w/ Mucuna. 5- The hope is rising for low cost local therapies that can expand access while we continue working toward equitable Parkinson care across the globe. https://journals.sagepub.com/doi/full/10.1177/1877718X251383721 #parkinson #michaelokun #fixelinstitute